The global race to find better treatments for type 2 diabetes and obesity — a race that GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound have dominated for the past four years — has produced a potentially important new contender. Researchers at Karolinska Institutet and Stockholm University published findings June 3, 2026 in the journal Cell describing an experimental oral medication that works through an entirely different mechanism than GLP-1 drugs: rather than suppressing appetite by mimicking gut hormones, it directly activates metabolism inside skeletal muscle, increasing fat burning and improving blood sugar control while preserving lean mass.
The distinction is clinically significant. GLP-1 drugs are highly effective, but their well-documented side effects — persistent nausea, gastrointestinal distress, and muscle wasting (which can occur when weight loss happens faster than the body can preserve lean mass) — have driven substantial demand for alternatives, particularly for patients who cannot tolerate GLP-1s or who specifically want to maintain muscle mass during metabolic treatment.
